**
In a striking revelation, documents have emerged indicating that top officials from the Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, last year to discuss litigation surrounding the company’s glyphosate-based herbicides. This meeting, which took place on June 17, 2025, raises significant questions about the intersection of corporate interests and regulatory oversight in the ongoing battle over allegations linking glyphosate to cancer.
A Meeting of Concern
The meeting between Anderson and EPA officials unfolded during a critical period when Bayer was grappling with numerous lawsuits from individuals claiming that their cancer diagnoses were a direct result of using glyphosate products, including the highly controversial Roundup. Internal records reveal that the discussions centered on “litigation” and “supreme court action,” signalling Bayer’s intent to mitigate the financial repercussions of these legal challenges, which have already cost the company billions in settlements.
Bayer’s strategy hinges on a legal argument asserting that if the EPA does not mandate a cancer warning for glyphosate products, the company should not be held accountable for failing to provide such warnings. While one appellate court has sided with Bayer on this issue, other courts, including the Biden administration’s solicitor general, have rejected the preemption argument, underscoring the contentious nature of the litigation.
A Shift in Regulatory Support
The timing of this meeting is particularly notable, occurring just weeks before the Supreme Court requested input from the Trump administration’s Justice Department regarding Bayer’s case. Following their discussions, the administration demonstrated robust support for Bayer, culminating in a December 1 filing that urged the Supreme Court to take up the matter. The court subsequently agreed to hear the case, with arguments scheduled for April 27.
The Trump administration’s backing continued to manifest in various forms, including invoking the Defense Production Act on February 18, 2026, to safeguard glyphosate production and granting immunity to manufacturers like Bayer. Additionally, on March 2, Solicitor General D. John Sauer filed an amicus brief that reinforced the government’s endorsement of Bayer’s position, a move that has drawn scrutiny from health advocates and legal experts alike.
Voices of Dissent
Critics have expressed alarm over the implications of such high-level meetings, suggesting that they highlight a troubling trend where corporate interests may overshadow public health concerns. Nathan Donley, environmental health science director for the Center for Biological Diversity, articulated his dismay, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.”
Legal experts have echoed these sentiments, questioning whether ordinary citizens, particularly those affected by glyphosate, were afforded similar opportunities to present their concerns to the EPA. Whitney Di Bona, a consumer safety advocate, remarked on the imbalance of access, saying, “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup.”
A Pattern of Corporate Influence
The meeting not only raises ethical questions about the influence of major corporations on regulatory bodies but also reflects a broader pattern where industry leaders are granted privileged access to decision-makers. Naomi Oreskes, a Harvard professor who researches corporate influence in regulation, noted that this dynamic often leaves the public’s voice unheard, compounding the challenges faced by those advocating for stricter regulations on harmful substances.
Zen Honeycutt, founder of the advocacy group Moms Across America, underscored the historical context of corporate pressure on regulatory agencies, asserting that such interactions between Bayer and the EPA are part of a well-documented trend. “Coercion by chemical companies on our regulatory agencies is nothing new,” she stated, highlighting the continued struggle for equitable representation in regulatory discussions.
Why it Matters
The implications of this meeting and the subsequent actions taken by the Trump administration are profound. They underscore the potential for corporate interests to shape regulatory frameworks in ways that may not prioritise public health. As litigation over glyphosate continues to unfold, the public’s trust in regulatory bodies is at stake. This situation serves as a clarion call for greater transparency and accountability in how health and safety regulations are crafted—a vital step in ensuring that the voices of those impacted by these products are heard and heeded in the corridors of power.
